TROGARZO

This brand name is authorized in Austria, Estonia, Ireland, Israel, Lithuania, Poland, United States

Active ingredients

The drug TROGARZO contains one active pharmaceutical ingredient (API):

1 Ibalizumab UNII LT369U66CE - IBALIZUMAB

Ibalizumab, a humanized monoclonal antibody of immunoglobulin G type 4 (IgG4), is a CD4 domain 2-directed HIV-1 inhibitor. Ibalizumab blocks HIV-1 from infecting CD4+ T cells by binding to domain 2 of CD4 and interfering with the post-attachment steps required for the entry of HIV-1 virus particles into host cells and preventing the viral transmission that occurs via cell-cell fusion. Read about Ibalizumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TROGARZO Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AX23		J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AX Other antivirals
Discover more medicines within J05AX23

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1802359
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8794
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1088560
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100427238
Country: US	FDA, National Drug Code	Identifier(s): 62064-122